Segment Reporting (Details) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2025 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2025 USD ($) segment	Jun. 30, 2024 USD ($)
Segment Reporting [Abstract]
Number of reportable segments | segment			2
Segment Reporting Information [Line Items]
Impact of foreign currency fluctuations	$ 6	$ (40)	$ (62)	$ (59)
Net sales	5,061	4,120	9,724	7,977
Cost of products sold	1,516	1,251	2,876	2,444
Selling, general and administrative expenses	1,426	1,250	2,801	2,430
Research and development expenses	435	345	838	681
Other segment items	14	9	25	18
Segment operating incom	1,664	1,304	3,246	2,463
Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments	(2,605)	(2,330)	(4,894)	(4,303)
Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs	(355)	(386)	(564)	(510)
Amortization expense	(225)	(213)	(444)	(427)
Operating income (loss)	819	520	1,740	1,195
Other income (expense), net	122	(100)	6	(167)
Income (loss) before income taxes	941	420	1,746	1,028
MedSurg
Segment Reporting Information [Line Items]
Net sales	1,716	1,483	3,293	2,895
Cardiovascular
Segment Reporting Information [Line Items]
Net sales	3,345	2,637	6,430	5,082
Operating Segments
Segment Reporting Information [Line Items]
Net sales of reportable segments	5,055	4,160	9,786	8,035
Income (loss) before income taxes		420		1,028
Operating Segments | MedSurg
Segment Reporting Information [Line Items]
Net sales of reportable segments	1,714	1,495	3,312	2,912
Cost of products sold	$ 470	$ 401	$ 905	$ 781
Cost of products sold, percentage of net sale	27.40%	26.80%	27.30%	26.80%
Selling, general and administrative expenses	$ 517	$ 454	$ 1,026	$ 894
Selling, general and administrative expenses, percentage of net sale	30.20%	30.40%	31.00%	30.70%
Research and development expenses	$ 120	$ 114	$ 241	$ 221
Research and development expenses, percentage of net sale	7.00%	7.60%	7.30%	7.60%
Other segment items	$ 8	$ 4	$ 13	$ 9
Other segment items, percentage of net sale	0.50%	0.30%	0.40%	0.30%
Segment operating incom	$ 599	$ 522	$ 1,127	$ 1,007
Segment operating income, percentage of net sale	34.90%	34.90%	34.00%	34.60%
Operating Segments | Cardiovascular
Segment Reporting Information [Line Items]
Net sales of reportable segments	$ 3,341	$ 2,665	$ 6,474	$ 5,123
Cost of products sold	$ 1,046	$ 851	$ 1,971	$ 1,662
Cost of products sold, percentage of net sale	31.30%	31.90%	30.40%	32.40%
Selling, general and administrative expenses	$ 908	$ 796	$ 1,775	$ 1,536
Selling, general and administrative expenses, percentage of net sale	27.20%	29.90%	27.40%	30.00%
Research and development expenses	$ 315	$ 231	$ 597	$ 459
Research and development expenses, percentage of net sale	9.40%	8.70%	9.20%	9.00%
Other segment items	$ 6	$ 5	$ 12	$ 9
Other segment items, percentage of net sale	0.20%	0.20%	0.20%	0.20%
Segment operating incom	$ 1,065	$ 782	$ 2,119	$ 1,456
Segment operating income, percentage of net sale	31.90%	29.40%	32.70%	28.40%
Segment Reporting, Reconciling Item, Corporate Nonsegment
Segment Reporting Information [Line Items]
Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments	$ (264)	$ (185)	$ (497)	$ (332)